OR WAIT null SECS
Growth and Advancements in Fill/Finish
Leveraging automation advancements can help improve efficiency in aseptic processing.
Changes and Trends in the Outsourcing Landscape
Quality Considerations in Changing Excipient Providers
January 19, 2024
The agency recommended 77 drugs for marketing authorization in 2023, including 39 new APIs.
January 18, 2024
The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
FDA’s Center for Drug Evaluation and Research released its report on new drugs approved in 2023.
January 17, 2024
Charles River’s off-the-shelf rep/cap plasmids are intended to simplify gene therapy supply chains.
The acquisition marks a pivotal expansion for the company into the US market.
The agency is reviewing data on secondary malignancies related to T-cells for approved CAR T-cell medicines.
January 16, 2024
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
According to the Pharmapack Europe 2024 survey results, contract packaging will see growth over the coming 12 months.
CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.
January 15, 2024
The European Medicines Agency safety committee says there is a potential risk of neurodevelopment disorders in children born to men treated with valproate.